Table 3 Summary of findings for all studies.
From: Mucoepidermoid carcinoma (MEC) and adenosquamous carcinoma (ASC), the same or different entities?
Groups of studies examing MAML2 rearrangementa | Number of studies | Number of cases included (range) | Sites examined | Number of reported mutations | |||
|---|---|---|---|---|---|---|---|
MEC (n) | % | ASC (n) | % | ||||
1. MAML2 | 5 | 5–82 | Pancreas, salivary glands, lung, cervix, thymus | 52/88 | 59.1 | 0/110 | 0 |
2. MAML2 | 49 | 2–217 | Salivary gland, lung, thyroid, skin, head & neck, breast | 1160/1715 | 67.6 | 0/37 | 0 |
3. MAML2 | 4 | 9–101 | Salivary gland, lung | 109/172 | 63.4 | ||
TOTAL MAML2 rearrangment | 1337/2009 | 66.6 | 0/147 | 0 | |||
Other genes | |||||||
EGFR | 43 | 2–631 | Salivary gland, lung, pancreas, cervix, esophagus, gall bladder | 11/329 | 3.3 | 660/1795 | 36.8 |
KRAS | 31 | 8–101 | Salivary gland, lung, pancreas, cervix, gall bladder | 11/266 | 4.1 | 143/625 | 22.9 |
ERBB2 | 10 | 3–76 | Salivary gland, lung, pancreas | 9/126 | 7.1 | 6/196 | 3.1 |
